loadpatents
name:-0.062783002853394
name:-0.035362005233765
name:-0.0037128925323486
Andersen; Henrik Sune Patent Filings

Andersen; Henrik Sune

Patent Applications and Registrations

Patent applications and USPTO patent grants for Andersen; Henrik Sune.The latest application filed is for "growth hormones with prolonged in-vivo efficacy".

Company Profile
3.42.52
  • Andersen; Henrik Sune - Holte DK
  • Andersen; Henrik Sune - Bagsvaerd DK
  • Andersen; Henrik Sune - Lyngby N/A DK
  • Andersen; Henrik Sune - Holte Ihsa DK
  • Andersen; Henrik Sune - Kgs. Lyngby DK
  • Andersen; Henrik Sune - K.o slashed.benhavn DK
  • Andersen; Henrik Sune - Copenhagen DK
  • Andersen; Henrik Sune - K.o slashed.benhavn .O slashed. DK
  • Andersen; Henrik Sune - Kobenhavn O DK
  • Andersen; Henrik Sune - Kobenhavn DK
  • Andersen; Henrik Sune - K.o slashed.benjavn DK
  • Andersen; Henrik Sune - K.phi.benhaven .phi. DK
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Growth Hormones with Prolonged In-Vivo Efficacy
App 20200306382 - Andersen; Henrik Sune ;   et al.
2020-10-01
Growth Hormones with Prolonged In-Vivo Efficacy
App 20200102568 - Behrens; Carsten ;   et al.
2020-04-02
Growth Hormones with Prolonged In-Vivo Efficacy
App 20190203213 - Behrens; Carsten ;   et al.
2019-07-04
Growth Hormones with Prolonged In-Vivo Efficacy
App 20180221501 - Andersen; Henrik Sune ;   et al.
2018-08-09
Antagonistic DR3 Ligands
App 20170305994 - Andersen; Mette Dahl ;   et al.
2017-10-26
Growth Hormones with Prolonged In-Vivo Efficacy
App 20170239362 - Behrens; Carsten ;   et al.
2017-08-24
Antagonistic DR3 ligands
Grant 9,737,612 - Andersen , et al. August 22, 2
2017-08-22
Antagonistic DR3 ligands
Grant 9,713,644 - Andersen , et al. July 25, 2
2017-07-25
Growth hormones with prolonged in-vivo efficacy
Grant 9,695,226 - Behrens , et al. July 4, 2
2017-07-04
Growth Hormones with Prolonged In-Vivo Efficacy
App 20140329750 - Andersen; Henrik Sune ;   et al.
2014-11-06
Conjugated proteins with prolonged in vivo efficacy
Grant 8,865,868 - Behrens , et al. October 21, 2
2014-10-21
Antagonistic Dr3 Ligands
App 20140294853 - Andersen; Mette Dahl ;   et al.
2014-10-02
Growth hormones with prolonged in-vivo efficacy
Grant 8,841,249 - Johansen , et al. September 23, 2
2014-09-23
Growth hormones with prolonged in-vivo efficacy
Grant 8,779,109 - Behrens , et al. July 15, 2
2014-07-15
Antagonistic DR3 ligands
Grant 8,765,130 - Andersen , et al. July 1, 2
2014-07-01
Growth Hormones with Prolonged In-Vivo Efficacy
App 20140107324 - Behrens; Carsten ;   et al.
2014-04-17
Antagonistic Dr3 Ligands
App 20130336984 - Andersen; Mette Dahl ;   et al.
2013-12-19
Antagonistic Dr3 Ligands
App 20130330360 - Andersen; Mette Dahl ;   et al.
2013-12-12
Growth Hormone Conjugates
App 20130143815 - Andersen; Henrik Sune ;   et al.
2013-06-06
Pharmaceutical use of substituted amides
Grant 8,383,683 - Ebdrup , et al. February 26, 2
2013-02-26
11-beta-hydroxysteroid dehydrogenase type 1 active compounds
Grant 8,383,668 - Ebdrup , et al. February 26, 2
2013-02-26
Growth Hormones With Prolonged In-Vivo Efficacy
App 20120309944 - Behrens; Carsten ;   et al.
2012-12-06
Growth Hormones with Prolonged In-Vivo Efficacy
App 20120172303 - Johansen; Nils Langeland ;   et al.
2012-07-05
Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
Grant 8,153,798 - Kilburn , et al. April 10, 2
2012-04-10
11.beta.-hydroxysteroid dehydrogenase type 1 active spiro compounds
Grant 8,138,342 - Kilburn , et al. March 20, 2
2012-03-20
11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
App 20120010194 - Ebdrup; Soren ;   et al.
2012-01-12
11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
App 20120004209 - Ebdrup; Soren ;   et al.
2012-01-05
Pharmaceutical Use Of Substituted Amides
App 20110312949 - Kilburn; John Paul ;   et al.
2011-12-22
Pharmaceutical use of substituted amides
Grant 8,053,431 - Kilburn , et al. November 8, 2
2011-11-08
11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
Grant 8,053,447 - Ebdrup , et al. November 8, 2
2011-11-08
11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
Grant 8,048,908 - Ebdrup , et al. November 1, 2
2011-11-01
Conjugated Proteins With Prolonged In Vivo Efficacy
App 20110223151 - Behrens; Carsten ;   et al.
2011-09-15
11beta-hydroxysteroid Dehydrogenase Type 1 Active Compounds
App 20100292215 - Ebdrup; Soren ;   et al.
2010-11-18
Pharmaceutical Use Of Fused 1,2,4-triazoles
App 20100197658 - Andersen; Henrik Sune ;   et al.
2010-08-05
Pharmaceutical use of fused 1,2,4-triazoles
Grant 7,723,323 - Andersen , et al. May 25, 2
2010-05-25
11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
App 20100120743 - Gundertofte; Anette ;   et al.
2010-05-13
11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
Grant 7,700,583 - Gundertofte , et al. April 20, 2
2010-04-20
Pharmaceutical Use Of Substituted Amides
App 20100087543 - Ebdrup; Soren ;   et al.
2010-04-08
Indole- And Benzimidazole Amides As Hydroxysteroid Dehydrogenase Inhibitors
App 20100076041 - Kilburn; John Paul ;   et al.
2010-03-25
11beta-hsd1 Active Compounds
App 20100056600 - Ebdrup; Soren ;   et al.
2010-03-04
11beta-hydroxysteroid Dehydrogenase Type 1 Active Compounds
App 20100009968 - Ebdrup; Soren ;   et al.
2010-01-14
4-piperidylbenzamides As 11-beta-hydroxysteroid Dehydrogenase Type 1 Inhibitors
App 20090325932 - Ebdrup; Soren ;   et al.
2009-12-31
Pharmaceutical Use Of Substituted Piperidine Carboxamides
App 20090306048 - Kilburn; John Paul ;   et al.
2009-12-10
Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy
App 20090264412 - Kampen; Gita Camilla Tejlgaard ;   et al.
2009-10-22
Amide Derivatives and Pharmaceutical Use Thereof
App 20090264414 - Andersen; Henrik Sune ;   et al.
2009-10-22
Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders
App 20090137574 - Kampen; Gita Camilla Tejlgaard ;   et al.
2009-05-28
Pharmaceutical Use Of Substituted Amides
App 20090124598 - Andersen; Henrik Sune ;   et al.
2009-05-14
Pharmaceutical Use Of Substituted Amides
App 20090118259 - Kilburn; John Paul ;   et al.
2009-05-07
Combination therapy using an 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
Grant 7,501,405 - Kampen , et al. March 10, 2
2009-03-10
Pharmaceutical Use of Fused 1,2,4-Triazoles
App 20080153807 - Andersen; Henrik Sune ;   et al.
2008-06-26
Pharmaceutical use of substituted amides
App 20080108598 - Andersen; Henrik Sune ;   et al.
2008-05-08
Pharmaceutical use of fused 1,2,4-triazoles
Grant 7,358,238 - Andersen , et al. April 15, 2
2008-04-15
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
App 20070270408 - Andersen; Henrik Sune ;   et al.
2007-11-22
Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
Grant 7,115,624 - Andersen , et al. October 3, 2
2006-10-03
Pharmaceutical use of substituted amides
App 20060111366 - Andersen; Henrik Sune ;   et al.
2006-05-25
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
App 20060111348 - Kampen; Gita Camilla Tejlgaard ;   et al.
2006-05-25
Pharmaceutical use of fused 1,2,4-triazoles
App 20060106008 - Andersen; Henrik Sune ;   et al.
2006-05-18
Pharmaceutical use of substituted 1,2,4-triazoles
App 20060100235 - Andersen; Henrik Sune ;   et al.
2006-05-11
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
App 20060094699 - Kampen; Gita Camilla Tejlgaard ;   et al.
2006-05-04
11beta-hydroxysteroid dehydrogenase type 1 active compounds
App 20060089349 - Gundertofte; Anette ;   et al.
2006-04-27
Modulators of Protein Tyrosine Phosphatases (PTPases)
Grant 7,019,026 - Andersen , et al. March 28, 2
2006-03-28
Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)
Grant 6,951,878 - M.o slashed.ller , et al. October 4, 2
2005-10-04
Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
App 20050119332 - Jeppesen, Lone ;   et al.
2005-06-02
Modulators of protein tyrosine phosphatases (PTPases)
Grant 6,613,903 - Andersen , et al. September 2, 2
2003-09-02
N-substituted azaheterocyclic carboxylic acids and their use
Grant 6,613,791 - Dorwald , et al. September 2, 2
2003-09-02
Modulators of protein tyrosine phosphatases (PTPases)
App 20030069267 - Moller, Niels Peter Hundahl ;   et al.
2003-04-10
Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
App 20030064979 - Hansen, Thomas Kruse ;   et al.
2003-04-03
Modulators of protein tyrosine phosphatases (PTPases)
App 20020165398 - Jeppesen, Lone ;   et al.
2002-11-07
Modulators of Protein Tyrosine Phosphatases (PTPases)
App 20020151561 - Andersen, Henrik Sune ;   et al.
2002-10-17
Oral hypoglycaemic agents
App 20020132812 - Andersen, Henrik Sune ;   et al.
2002-09-19
Modulators of protein tyrosine phosphatases (PTPases)
App 20020099073 - Andersen, Henrik Sune ;   et al.
2002-07-25
Modulators of protein tyrosine phosphatases (PTPases)
Grant 6,410,586 - M.o slashed.ller , et al. June 25, 2
2002-06-25
Modulators Of Protein Tyrosine Phosphatases (ptpases)
App 20020019412 - ANDERSEN, HENRIK SUNE ;   et al.
2002-02-14
Modulators Of Protein Tyrosine Phosphatases (ptpases)
App 20020002199 - JEPPESEN, LONE ;   et al.
2002-01-03
Modulators of protein tyrosine phosphatases (PTPASES)
Grant 6,262,044 - M.o slashed.ller , et al. July 17, 2
2001-07-17
Modulators of protein tyrosine phosphatases (PTPases)
Grant 6,225,329 - Richter , et al. May 1, 2
2001-05-01
Somatostatin agonists and antagonists
Grant 6,127,343 - Ankersen , et al. October 3, 2
2000-10-03
N-substituted azaheterocyclic carboxylic acids and esters thereof
Grant 6,110,913 - Dorwald , et al. August 29, 2
2000-08-29
Modulators of molecules with phosphotyrosine recognition units
Grant 6,080,770 - Andersen , et al. June 27, 2
2000-06-27
Substituted dibenz[b,f]azepines and uses thereof
Grant 6,071,901 - Dorwald , et al. June 6, 2
2000-06-06
Modulators of molecules with phosphotyrosine recognition units
Grant 6,063,800 - Andersen , et al. May 16, 2
2000-05-16
Modulators of molecules with phosphotyrosine recognition units
Grant 5,972,978 - Andersen , et al. October 26, 1
1999-10-26
Modulators of molecules with phosphotyrosine recognition units
Grant 5,958,957 - Andersen , et al. September 28, 1
1999-09-28
N-substituted aza-heterocyclic carboxylic acids and esters thereof
Grant 5,874,428 - D.o slashed.rwald , et al. February 23, 1
1999-02-23
Heterocyclic compounds
Grant 5,721,260 - Hohlweg , et al. February 24, 1
1998-02-24
N-substituted azaheterocyclic carboxylic acids and esters thereof
Grant 5,688,788 - Andersen , et al. November 18, 1
1997-11-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed